2025 Q4 -tulosraportti
Vain PDF
145 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.7. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 23.7.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 | ||
2024 Q2 -tulosraportti 26.7.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·14.7.Buying opportunity or should one just stay away? What do you think?
16.7.Personally, I don't hold for long, once money starts running out I exit and re enter after emissions. Ive only taken tiny losses and some okay wins since I also sell if theres temporary rises without actual catalysts, but had exposure for 70% of the time past 1,5 years
·13.7. · Muokattu🚀 Run 0,5?
Yes, agree that one should be careful, as there can be reasons for volatility in periods like this, but it's something that changes on paper when financing is secured. Guess what's pulling down the share price on some days now, are liquidity problems among selling shareholders. What has pulled down the share price over several years, is a pattern of continuous dilutions. In the future, when financing is secured after Medicare approval, it will be completely different on paper. If one envisions a scenario with 600 million shares at 50 øre when the company is financed beyond the development phase, then one can calculate what that means on paper. Earlier in July, the CEO reported that there are 2 issues remaining that they are working with Medicare to resolve. Once that is resolved, one can look at it on paper. That a competitor was sold for 600MUSD about 5 years ago, and that Prostatype now comes with technical innovations, does not necessarily mean that Prostatype succeeds, but that the potential is there.- ·10.7.Preferential share issue at 0.1. Does that mean a select few get to buy so cheaply? Is it a buying opportunity now or should one stay away? What are your thoughts? When a stock has taken a lot of beating, it can be a good opportunity, but it can also be a falling knife...It's a great deal if you are new to stocks and haven't paid dearly in advance for the development. Then you can just buy some subscription rights and participate in the issue. The rest of us just have to watch, while new shareholders and large shareholders get in "for free". The test is approved. Now we are waiting for the subsidy price/subsidy approval in USAvinventer.
·8.7.Excerpt from the link below: Medicare process is nearing completion... The single most important event for Prostatype Genomics, according to Rickman, is the reimbursement process from Medicare, the largest public insurance company for prostate cancer in the USA. The dialogue with Medicare has been ongoing since the beginning of 2025, and the CEO describes the process as both comprehensive and thorough. He states that the company has had a good dialogue throughout the process and expects a decision in the near future, although a precise timeline cannot be given. Sees partnership or acquisition within two years Within two years, Rickman believes that Prostatype Genomics will either have entered into a strategic partnership with a major American player or have been acquired. Rickman describes the current situation as the most interesting he has experienced in his 35 years in the industry. He emphasizes that Prostatype Genomics already has a validated product launched in both Europe and the USA, while the company is in the final stages of the Medicare process. Exciting....
Sounds like a sale of a new share issue. If it had been related parties, they would have waited. It's almost fantastic. Up to 2 kroner, and now a new share issue at 10 øre.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
145 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·14.7.Buying opportunity or should one just stay away? What do you think?16.7.Personally, I don't hold for long, once money starts running out I exit and re enter after emissions. Ive only taken tiny losses and some okay wins since I also sell if theres temporary rises without actual catalysts, but had exposure for 70% of the time past 1,5 years
- ·13.7. · Muokattu🚀 Run 0,5?Yes, agree that one should be careful, as there can be reasons for volatility in periods like this, but it's something that changes on paper when financing is secured. Guess what's pulling down the share price on some days now, are liquidity problems among selling shareholders. What has pulled down the share price over several years, is a pattern of continuous dilutions. In the future, when financing is secured after Medicare approval, it will be completely different on paper. If one envisions a scenario with 600 million shares at 50 øre when the company is financed beyond the development phase, then one can calculate what that means on paper. Earlier in July, the CEO reported that there are 2 issues remaining that they are working with Medicare to resolve. Once that is resolved, one can look at it on paper. That a competitor was sold for 600MUSD about 5 years ago, and that Prostatype now comes with technical innovations, does not necessarily mean that Prostatype succeeds, but that the potential is there.
- ·10.7.Preferential share issue at 0.1. Does that mean a select few get to buy so cheaply? Is it a buying opportunity now or should one stay away? What are your thoughts? When a stock has taken a lot of beating, it can be a good opportunity, but it can also be a falling knife...It's a great deal if you are new to stocks and haven't paid dearly in advance for the development. Then you can just buy some subscription rights and participate in the issue. The rest of us just have to watch, while new shareholders and large shareholders get in "for free". The test is approved. Now we are waiting for the subsidy price/subsidy approval in USAvinventer.
- ·8.7.Excerpt from the link below: Medicare process is nearing completion... The single most important event for Prostatype Genomics, according to Rickman, is the reimbursement process from Medicare, the largest public insurance company for prostate cancer in the USA. The dialogue with Medicare has been ongoing since the beginning of 2025, and the CEO describes the process as both comprehensive and thorough. He states that the company has had a good dialogue throughout the process and expects a decision in the near future, although a precise timeline cannot be given. Sees partnership or acquisition within two years Within two years, Rickman believes that Prostatype Genomics will either have entered into a strategic partnership with a major American player or have been acquired. Rickman describes the current situation as the most interesting he has experienced in his 35 years in the industry. He emphasizes that Prostatype Genomics already has a validated product launched in both Europe and the USA, while the company is in the final stages of the Medicare process. Exciting....Sounds like a sale of a new share issue. If it had been related parties, they would have waited. It's almost fantastic. Up to 2 kroner, and now a new share issue at 10 øre.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.7. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 23.7.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 | ||
2024 Q2 -tulosraportti 26.7.2024 |
2025 Q4 -tulosraportti
Vain PDF
145 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.7. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 23.7.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 | ||
2024 Q2 -tulosraportti 26.7.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·14.7.Buying opportunity or should one just stay away? What do you think?16.7.Personally, I don't hold for long, once money starts running out I exit and re enter after emissions. Ive only taken tiny losses and some okay wins since I also sell if theres temporary rises without actual catalysts, but had exposure for 70% of the time past 1,5 years
- ·13.7. · Muokattu🚀 Run 0,5?Yes, agree that one should be careful, as there can be reasons for volatility in periods like this, but it's something that changes on paper when financing is secured. Guess what's pulling down the share price on some days now, are liquidity problems among selling shareholders. What has pulled down the share price over several years, is a pattern of continuous dilutions. In the future, when financing is secured after Medicare approval, it will be completely different on paper. If one envisions a scenario with 600 million shares at 50 øre when the company is financed beyond the development phase, then one can calculate what that means on paper. Earlier in July, the CEO reported that there are 2 issues remaining that they are working with Medicare to resolve. Once that is resolved, one can look at it on paper. That a competitor was sold for 600MUSD about 5 years ago, and that Prostatype now comes with technical innovations, does not necessarily mean that Prostatype succeeds, but that the potential is there.
- ·10.7.Preferential share issue at 0.1. Does that mean a select few get to buy so cheaply? Is it a buying opportunity now or should one stay away? What are your thoughts? When a stock has taken a lot of beating, it can be a good opportunity, but it can also be a falling knife...It's a great deal if you are new to stocks and haven't paid dearly in advance for the development. Then you can just buy some subscription rights and participate in the issue. The rest of us just have to watch, while new shareholders and large shareholders get in "for free". The test is approved. Now we are waiting for the subsidy price/subsidy approval in USAvinventer.
- ·8.7.Excerpt from the link below: Medicare process is nearing completion... The single most important event for Prostatype Genomics, according to Rickman, is the reimbursement process from Medicare, the largest public insurance company for prostate cancer in the USA. The dialogue with Medicare has been ongoing since the beginning of 2025, and the CEO describes the process as both comprehensive and thorough. He states that the company has had a good dialogue throughout the process and expects a decision in the near future, although a precise timeline cannot be given. Sees partnership or acquisition within two years Within two years, Rickman believes that Prostatype Genomics will either have entered into a strategic partnership with a major American player or have been acquired. Rickman describes the current situation as the most interesting he has experienced in his 35 years in the industry. He emphasizes that Prostatype Genomics already has a validated product launched in both Europe and the USA, while the company is in the final stages of the Medicare process. Exciting....Sounds like a sale of a new share issue. If it had been related parties, they would have waited. It's almost fantastic. Up to 2 kroner, and now a new share issue at 10 øre.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt